Tumefactive Demyelinating Lesions in a Patient with Multiple Sclerosis Developed two Days after the Injection of Rituximab
CONCLUSION: Rituximab should be considered as a potential cause of tumefactive demyelinating lesions in patients with MS.PMID:34018172
Source: Acta Neurologica Taiwanica - Category: Neurology Authors: Abdorreza Naser Moghadasi Source Type: research
More News: Brain | Gilenya | MRI Scan | Multiple Sclerosis | Neurology | Rituxan | Study | Taiwan Health | Tysabri